AU5509296A - Bispecific antibodies in which the binding capability is rev ersibly inhibited by a photocleavable moiety - Google Patents

Bispecific antibodies in which the binding capability is rev ersibly inhibited by a photocleavable moiety

Info

Publication number
AU5509296A
AU5509296A AU55092/96A AU5509296A AU5509296A AU 5509296 A AU5509296 A AU 5509296A AU 55092/96 A AU55092/96 A AU 55092/96A AU 5509296 A AU5509296 A AU 5509296A AU 5509296 A AU5509296 A AU 5509296A
Authority
AU
Australia
Prior art keywords
ersibly
rev
inhibited
bispecific antibodies
binding capability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU55092/96A
Inventor
Colin Henry Self
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9509004.9A external-priority patent/GB9509004D0/en
Priority claimed from GBGB9516606.2A external-priority patent/GB9516606D0/en
Application filed by Individual filed Critical Individual
Publication of AU5509296A publication Critical patent/AU5509296A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU55092/96A 1995-05-03 1996-05-02 Bispecific antibodies in which the binding capability is rev ersibly inhibited by a photocleavable moiety Abandoned AU5509296A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9509004.9A GB9509004D0 (en) 1995-05-03 1995-05-03 Antibodies, preparation, use and method
GB9509004 1995-05-03
GBGB9516606.2A GB9516606D0 (en) 1995-08-04 1995-08-04 Antibodies their preparation and use
GB9516606 1995-08-04
PCT/GB1996/001066 WO1996034892A1 (en) 1995-05-03 1996-05-02 Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety

Publications (1)

Publication Number Publication Date
AU5509296A true AU5509296A (en) 1996-11-21

Family

ID=26306976

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55092/96A Abandoned AU5509296A (en) 1995-05-03 1996-05-02 Bispecific antibodies in which the binding capability is rev ersibly inhibited by a photocleavable moiety

Country Status (5)

Country Link
EP (1) EP0871673B1 (en)
JP (1) JP4212111B2 (en)
AU (1) AU5509296A (en)
DE (1) DE69636015T2 (en)
WO (1) WO1996034892A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003227504A1 (en) 2002-04-15 2003-10-27 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
US8337841B2 (en) 2003-01-21 2012-12-25 Chugai Seiyaku Kabushiki Kaisha Methods of screening for antibody light chains
WO2004111233A1 (en) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
AU2003280713A1 (en) * 2003-11-04 2005-05-19 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
GB0404187D0 (en) * 2004-02-25 2004-03-31 Biotransformations Ltd Binding agents
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
JP5620626B2 (en) 2005-03-31 2014-11-05 中外製薬株式会社 Polypeptide production method by association control
JP5085322B2 (en) 2005-06-10 2012-11-28 中外製薬株式会社 Pharmaceutical composition containing sc (Fv) 2
EP1908482B1 (en) 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
GB0605702D0 (en) * 2006-03-21 2006-05-03 Biotransformations Ltd Materials and methods for immune cell stimulation
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
GB0716160D0 (en) * 2007-08-17 2007-09-26 Biotransformations Ltd Materials and methods for treating cancers which express folate receptors
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
JP5851842B2 (en) 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. Modified antibody composition and methods of making and using the same
BRPI1011384A2 (en) 2009-02-23 2016-03-15 Cytomx Therapeutics Inc proproteins and their methods of use
DK3138581T3 (en) 2011-03-17 2019-04-15 Univ Birmingham REDIRECTED IMMUNTERY
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
KR102182485B1 (en) 2013-05-28 2020-11-25 카오슝 메디칼 유니버시티 Antibody locker for the inactivation of protein drug
BR112016006197B1 (en) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PRODUCING A BISPECIFIC POLYPEPTIDE ANTIBODY
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
PL3377103T5 (en) 2015-11-19 2025-07-07 Revitope Limited FUNCTIONAL ANTIBODY FRAGMENT COMPLEMENTATION FOR A TWO-COMPONENT SYSTEM FOR RE-REGULATED KILLING OF UNWANTED CELLS
CN108368166B (en) 2015-12-28 2023-03-28 中外制药株式会社 Method for improving purification efficiency of polypeptide containing FC region
EP3551667A4 (en) 2016-12-09 2020-06-17 Seattle Genetics, Inc. BIVALENT ANTIBODIES MASKED BY COILS
CA3053010A1 (en) 2017-02-08 2018-08-16 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
AU2018220736B2 (en) 2017-02-20 2024-10-24 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
AU2019218125B2 (en) 2018-02-08 2025-03-13 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
EP4434587A3 (en) 2018-02-08 2025-01-01 Dragonfly Therapeutics, Inc. Antibody variable domain combinations targeting the nkg2d receptor
EP3755721A4 (en) 2018-02-20 2021-12-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
EA202091888A1 (en) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
TW202019479A (en) 2018-08-08 2020-06-01 美商蜻蜓醫療公司 Multi-specific binding proteins that bind bcma, nkg2d, and cd16, and methods of use
MA53284A (en) 2018-08-08 2022-01-26 Dragonfly Therapeutics Inc NKG2D, CD16 AND TUMOR ASSOCIATED ANTIGEN BINDING PROTEINS
GB201918230D0 (en) * 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
US12157771B2 (en) 2020-05-06 2024-12-03 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
CN117222663A (en) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and tumor-associated antigens

Also Published As

Publication number Publication date
DE69636015D1 (en) 2006-05-18
EP0871673A1 (en) 1998-10-21
JP4212111B2 (en) 2009-01-21
DE69636015T2 (en) 2007-01-04
WO1996034892A1 (en) 1996-11-07
EP0871673B1 (en) 2006-04-05
JPH11505108A (en) 1999-05-18

Similar Documents

Publication Publication Date Title
AU5509296A (en) Bispecific antibodies in which the binding capability is rev ersibly inhibited by a photocleavable moiety
AU5869596A (en) Anti-gp130 monoclonal antibodies
AU4973396A (en) A method for making heteromultimeric polypeptides
AU5752696A (en) Dna binding antibodies
AU3811495A (en) Antibodies
AU5396496A (en) A vibrator
AU6916396A (en) A device for the synthesis of compounds in an array
AU6046696A (en) Peptides and compounds that bind to a receptor
AU4676496A (en) Foundation
AU7083996A (en) Underwater cementitious composition
AUPN039595A0 (en) A structural member
AU6904196A (en) A valvulotome
AU3752089A (en) Bispecific antibodies
AU674279B1 (en) Strapping tool
AU7626896A (en) Fungicidal mixture
AUPN475495A0 (en) A skimmer
AU2041095A (en) Separation-fee specific binding assays using anti-inhibitor antibodies
AU4195793A (en) Bispecific antibody
AU5405396A (en) A binder
AUPN670495A0 (en) A bin
AU4784196A (en) A chute for a ship
AU4380196A (en) A structural member
AU6138596A (en) Binder
EP0761606A3 (en) Small clarification plant with a compact construction
AU4728196A (en) Specific binding materials